Kasper Fugger

Kasper Fugger

Auto-generated profile, based on publicly available information

Kasper Fugger

University College London Cancer Institute, London, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Nature
Verified
Journal Article
Closed access
PDF file
JBJiri Bartek
Jiri Bartek
NRNousin Rezaei
Nousin Rezaei
MLMichalis Liontos
Michalis Liontos
PKPanagiotis Karakaidos
Panagiotis Karakaidos
Dimitris KletsasDimitris Kletsas
Dimitris Kletsas
VGVassilis G. Gorgoulis
Vassilis G. Gorgoulis

1 May 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RSRandi G. Syljuåsen
Randi G. Syljuåsen
Claus SørensenClaus Sørensen
Claus Sørensen
LHLasse Tengbjerg Hansen
Lasse Tengbjerg Hansen
KFKasper Fugger
Kasper Fugger
CLCecilia Lundin
Cecilia Lundin
JBJiri Bartek
Jiri Bartek
Human checkpoint kinase 1 (Chk1) is an essential kinase required to preserve genome stability. Here, we show that Chk1 inhibition by two distinct drugs, UCN-01 and CEP-3891, or by Chk1 small interfering RNA (siRNA) leads to phosphorylation of ATR targets. Chk1-inhibition triggered rapid, pan-nuclear phosphorylation of histone H2AX, p53, Smc1, replication protein A, and Chk1 itself in human S-phase cells. These phosphorylations were inhibited by ATR siRNA and caffeine, but they occurred independently of ATM. Chk1 inhibition also caused an increased initiation of DNA replication, which was accompanied by increased amounts of nonextractable RPA protein, formation of single-stranded DNA, and induction of DNA strand breaks. Moreover, these responses were prevented by siRNA-mediated downregulation of Cdk2 or the replication initiation protein Cdc45, or by addition of the CDK inhibitor roscovitine. We propose that Chk1 is required during normal S phase to avoid aberrantly increased initiation of DNA replication, thereby protecting against DNA breakage. These results may help explain why Chk1 is an essential kinase and should be taken into account when drugs to inhibit this kinase are considered for use in cancer treatment.

20 December 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
SBSimon Bekker-Jensen
Simon Bekker-Jensen
JDJannie Rendtlew Danielsen
Jannie Rendtlew Danielsen
KFKasper Fugger
Kasper Fugger
IGIrina Gromova
Irina Gromova
ANAnnika Nerstedt
Annika Nerstedt
NMNiels Mailand
Niels Mailand

8 July 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
MDMads Daugaard
Mads Daugaard
ABAnnika Baude
Annika Baude
KFKasper Fugger
Kasper Fugger
LPLou Klitgaard Povlsen
Lou Klitgaard Povlsen
HBHalfdan Beck
Halfdan Beck
Marja JäätteläMarja Jäättelä
Marja Jäättelä

18 December 2017 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YCYing Wai Chan
Ying Wai Chan
KFKasper Fugger
Kasper Fugger
SWStephen West
Stephen West

9 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
KFKasper Fugger
Kasper Fugger
IBIlirjana Bajrami
Ilirjana Bajrami
MSMariana Silva Dos Santos
Mariana Silva Dos Santos
SYSarah Jane Young
Sarah Jane Young
SKSimone Kunzelmann
Simone Kunzelmann
SWStephen West
Stephen West
Three strikes to knock cancer out: BRCA1 and BRCA2 are tumor-suppressor genes, and patients with mutations in these genes are predisposed to breast, ovarian, and other cancers. Because BRCA1 and BRCA2 mutations affect pathways involved in DNA break repair, these patients' tumors are usually vulnerable to treatments that further damage DNA repair, such as poly(ADP-ribose) polymerase (PARP) inhibitors, but they can acquire resistance to therapy. Using a genome-wide screening approach, Fugger et al. identified a protein called DNPH1 as a “nucleotide sanitizer” that prevents the incorporation of abnormal nucleotides into DNA (see the Perspective by Kriaucionis). The authors examined its mechanism of action and demonstrated how it can be targeted to expedite the killing of BRCA1 -mutant cancer cells in combination with PARP inhibitor treatment. Science , this issue p. 156 ; see also p. 127